ORAMED PHARMACEUTICALS INC. (ORMP) - Dilution Analysis

10-Q filing | 40.8M shares outstanding

8-K filing: Lifeward completed its acquisition of Oratech, issuing shares and warrants to Oramed Pharmaceuticals, and also closed a private placement of senior secured convertible notes and warrants to Oramed.

10-K filing | 41.4M shares outstanding

10-Q filing | 41.6M shares outstanding

8-K filing: Scilex repurchased Subject Warrants to purchase 3,130,000 shares of Scilex Common Stock from Oramed Pharmaceuticals Inc. for $13,000,000, representing the first tranche of a warrant repurchase agreement. ($13.0M proceeds)

10-Q filing | 41.5M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. entered into an Option Agreement with Scilex Holding Company for Scilex to repurchase warrants to purchase Scilex' common stock for $27,000,000, with an upfront payment of $1,500,000. Scilex previously completed a 1-for-35 reverse stock split. ($27.0M proceeds)

10-Q filing | 41.2M shares outstanding

10-K filing | 40.8M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. entered into a Supplemental Agreement with Oramed NewCo, Oramed Ltd., Hefei Tianhui Biotech Co., Ltd., and Technowl Limited, amending the Joint Venture Agreement to form a joint venture company and outlining the terms for business operations, corporate governance, and the issuance of Oramed NewCo Common Stock. ($75.0M proceeds)

8-K filing: Oramed Pharmaceuticals Inc. amended its Senior Secured Promissory Note with Scilex Holding Company, extending the maturity date to December 31, 2025, and receiving 3,250,000 shares of Scilex common stock from SCLX Stock Acquisition JV LLC in consideration for the extension.

8-K filing: Scilex Holding Company issued 5,000,000 shares of Oramed Pharmaceuticals Inc. common stock to the Tranche B Noteholders (with 2,500,000 shares to Oramed) in exchange for deferring Scilex's obligation to make the First Amortization Payment until January 31, 2025.

10-Q filing | 40.9M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. entered into a Letter Agreement with Scilex Holding Company, where Scilex agreed to pay Oramed $2,000,000, with $300,000 designated to purchase Purchased Warrants, and Oramed can exercise the CS-5 Warrant with respect to up to 1,062,500 shares of Scilex Common Stock. ($0.3M proceeds)

10-Q filing | 40.9M shares outstanding

10-Q filing | 40.8M shares outstanding

10-K filing | 40.6M shares outstanding

10-Q filing | 40.2M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. entered into a Securities Purchase Agreement with Scilex Holding Company, involving the issuance of a Senior Secured Promissory Note, warrants to purchase Scilex common stock, and the transfer of existing warrants to Oramed in exchange for Scilex assuming Sorrento's obligations and the ability to credit bid in exchange for Scilex common and preferred stock and warrants.

8-K filing: Oramed Pharmaceuticals Inc. entered into non-binding term sheets with Sorrento Therapeutics, Inc. and Scilex Holding Company relating to the Securities Transfer and the Note, with transactions expected to close on or about September 19, 2023, involving the purchase of Scilex common stock, preferred stock, and warrants owned by Sorrento for an aggregate purchase price payable as follows: $110 million in cash, the assumption by Scilex of certain legal fees and expenses in the amount of approximately $12.25 million, plus a credit bid of all amounts owed to Scilex under the Junior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement, dated July 28, 2023, between Scilex and the Debtors.

8-K filing: Oramed Pharmaceuticals Inc. amended its Stock Purchase Agreement with Sorrento Therapeutics, Inc. to acquire equity securities of Scilex Holding Company, reducing the number of Scilex warrants to be purchased.

10-Q filing | 40.1M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. entered into a Stock Purchase Agreement with Sorrento Therapeutics, Inc. to acquire securities of Scilex Holding Company for $105,000,000, and also entered into a Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement to provide a $100,000,000 term loan facility. ($315.0M proceeds)

8-K filing: Oramed Pharmaceuticals Inc. entered into a non-binding term sheet with Sorrento Therapeutics, Inc. to acquire securities of Scilex Holding Company, including common stock, Series A preferred stock, and warrants, for a total purchase price of $105,000,000, subject to Bankruptcy Court approval and other conditions. ($315.0M proceeds)

10-Q filing | 40.0M shares outstanding

10-K filing | 39.0M shares outstanding

10-Q filing | 38.9M shares outstanding

10-Q filing | 38.7M shares outstanding

10-Q filing | 38.7M shares outstanding

10-Q filing | 38.3M shares outstanding

10-K filing | 38.1M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. entered into a Securities Purchase Agreement to sell 2,000,000 shares of common stock at $25 per share in a registered direct offering, with net proceeds expected to be approximately $46,375,000. ($50.0M proceeds)

8-K filing: Oramed Pharmaceuticals Inc. entered into an equity distribution agreement with Canaccord Genuity LLC to sell shares of its common stock having an aggregate offering price of up to $100,000,000, replacing the previous agreement dated June 16, 2021, under which 837,419 shares were sold for $10,987,000. ($10.99M proceeds)

S-3 filing: Oramed Pharmaceuticals files an S-3 to offer common stock and warrants for an aggregate initial offering price of $250,000,000 and an ATM offering of shares of common stock for an aggregate offering price of up to $100,000,000.

10-Q filing | 32.5M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. entered into an equity distribution agreement with Canaccord Genuity LLC to sell shares of its common stock having an aggregate offering price of up to $28,000,000 from time to time. ($38.55M proceeds)

10-Q filing | 30.2M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. entered into a License Agreement and Stockholders Agreement with Oravax Medical Inc., Akers, Premas, Cutter Mill Capital LLC, and Run Ridge LLC in connection with the formation of Oravax, where Oramed will hold a 63% equity interest. ($1.5M proceeds)

S-3 filing: The filing relates to the resale of up to 3,007,680 shares of common stock by selling stockholders, with 2,892,000 shares issuable upon exercise of outstanding warrants and 115,680 shares issuable upon exercise of warrants issued to the placement agent.

10-Q filing | 26.7M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. entered into an equity distribution agreement with Canaccord Genuity LLC, potentially issuing up to $40 million in common stock. From December 2, 2019 through December 1, 2020, the Company sold an aggregate of 2,212,621 shares of common stock pursuant to the 2019 Equity Distribution Agreement for aggregate gross proceeds of $10,641,934. ($10.64M proceeds)

10-K filing | 23.7M shares outstanding

10-Q filing | 23.5M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. issued 180,561 shares of Common Stock and 12,640 Underwriter's Warrants pursuant to a partial exercise of the Over-Allotment Option, with net proceeds to the Company expected to be approximately $20.2 million.

10-Q filing | 17.4M shares outstanding

8-K filing: Oramed Pharmaceuticals Inc. entered into an underwriting agreement with National Securities Corporation for a public offering of 5,250,000 shares of common stock at $4.00 per share, with an option for the underwriter to purchase an additional 787,500 shares, and agreed to issue warrants to purchase up to 7% of the shares sold in the offering.

10-Q filing | 17.7M shares outstanding